Breaking News Instant updates and real-time market news.

INVA

Innoviva

$15.45

0.02 (0.13%)

, TKPYY

Takeda Pharmaceutical

$27.88

0.385 (1.40%)

11:42
02/13/18
02/13
11:42
02/13/18
11:42

Sarissa Capital reconstitutes Innoviva board following termination of CEO Aguiar

Sarissa Capital Management LP announced that Sarissa Capital has entered into an agreement with Innoviva, Inc. (INVA) to reconstitute the entire board of directors as follows: Effective immediately Jules Haimovitz, Sarah Schlesinger, M.D. and Mark DiPaolo will be added to the Innoviva board, joining recently added Sarissa designees George Bickerstaff, III and Odysseas Kostas, M.D. Effective as of the upcoming stockholder meeting, the Innoviva board will consist of five directors: Jules Haimovitz, Sarah Schlesinger, M.D., Mark DiPaolo, George Bickerstaff, III and Odysseas Kostas, M.D. Mark DiPaolo and Odysseas Kostas, M.D. are principals of Sarissa Capital. Jules Haimovitz, Sarah Schlesinger, M.D. and George Bickerstaff, III served together on the board of directors of ARIAD Pharmaceuticals (TKPYY) and were instrumental in the turnaround efforts at ARIAD which culminated in the sale of the company for over $5B last year. Sarissa Capital was one of ARIAD's largest shareholders and Alex Denner, Ph.D., Sarissa Capital's founder and Chief Investment Officer, was the chairman of ARIAD at the time of its sale. This outcome is the result of a proxy contest Sarissa Capital waged in connection with Innoviva's 2017 annual stockholder meeting and Sarissa Capital's necessary subsequent litigation against Innoviva. In December 2017, Sarissa Capital prevailed in its litigation when the Delaware Court ruled that Innoviva breached its agreement with Sarissa Capital to add George Bickerstaff and Odysseas Kostas, M.D. to the board and ordered Innoviva to add them to the board immediately. Following that ruling, Sarissa engaged in discussions with Innoviva that resulted in the termination of CEO Mike Aguiar and this reconstitution of the board of directors.

INVA

Innoviva

$15.45

0.02 (0.13%)

TKPYY

Takeda Pharmaceutical

$27.88

0.385 (1.40%)

INVA Innoviva
$15.45

0.02 (0.13%)

05/01/17
COWN
05/01/17
NO CHANGE
Target $16
COWN
Outperform
Innoviva weakness a buying opportunity, says Cowen
Cowen analyst Tyler Van Buren said the recent earnings miss at Innoviva was largely non-fundamental and impacted by pressures that he expects will reverse in Q2. He said prescriptions look great and he views the weakness in Innoviva shares as a buying opportunity. Van Buren reiterated his Outperform rating and $16 price target on Innoviva shares.
11/20/17
DBAB
11/20/17
INITIATION
Target $13
DBAB
Hold
Innoviva initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Esther Rajavelu started Innoviva (INVA) with a Hold rating and $13 price target. The analyst is concerned about revenue concentration and sees no near-term growth opportunities outside of the GlaxoSmithKline (GSK) partnership.
11/20/17
11/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Innoviva (INVA) initiated with a Hold at Deutsche Bank. 2. National Vision (EYE) was initiated with an Overweight at Morgan Stanley, an Outperform at Wells Fargo, a Buy at Jefferies and Citi, as well as a Neutral at Goldman Sachs, UBS, and BofA/Merrill. 3. Ablynx (ABLX) was initiated with an Overweight at JPMorgan, an Outperform at Baird, and a Buy at Ladenburg. 4. Blue Apron (APRN) initiated with a Sector Weight at KeyBanc. 5. BP Midstream (BPMP) was initiated with an Overweight at JPMorgan, a Buy at UBS and Citi, an Equal Weight at Morgan Stanley and Barclays, as well as a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
TKPYY Takeda Pharmaceutical
$27.88

0.385 (1.40%)

10/03/17
JMPS
10/03/17
NO CHANGE
Target $25
JMPS
Outperform
Myovant Phase 3 results further de-risk ongoing trials, says JMP Securities
After Myovant Sciences (MYOV) and partner Takeda (TKPYY) announced a Japanese study evaluating the efficacy and safety of relugolix to treat uterine fibroids met its primary endpoint, JMP Securities analyst Jason Butler said the results represent a "best case outcome" and have a clear positive read through to ongoing international Phase 3 trials in uterine fibroids and endometriosis. The analyst, who increased his view of the probability of success in UF and EM, raised his price target on Myovant shares to $25 from $23 and keeps an Outperform rating on the stock.
01/16/18
BTIG
01/16/18
DOWNGRADE
BTIG
Neutral
TiGenix downgraded at BTIG to Neutral on valuation
As noted earlier, BTIG analyst Timothy Chiang downgraded TiGenix (TIG) to Neutral from Buy, saying the run-up of 81% year to date in the stock price has exceeded his target and warrants a move to the sidelines. Chiang believes that the acquisition offer by Takeda (TKPYY) will pass the required regulatory review of TiGenix lead product Alofisei in the E.U., adding that there is now less than 5% difference in the stock price relative to the Takeda offer.

TODAY'S FREE FLY STORIES

PZZA

Papa John's

$55.29

3.26 (6.27%)

12:40
06/20/18
06/20
12:40
06/20/18
12:40
Options
Timely sweep buyer of Papa John's weeklys »

Timely sweep buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:40
06/20/18
06/20
12:40
06/20/18
12:40
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

AAL

American Airlines

$42.29

0.78 (1.88%)

12:37
06/20/18
06/20
12:37
06/20/18
12:37
Hot Stocks
American asks government not to use planes for separated children »

American released a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AEP

American Electric

$66.87

(0.00%)

12:30
06/20/18
06/20
12:30
06/20/18
12:30
Hot Stocks
SWEPCO says LPSC approves proposed Wind Catcher Energy Connection project »

Southwestern Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$43.44

-0.16 (-0.37%)

12:25
06/20/18
06/20
12:25
06/20/18
12:25
Conference/Events
The Executives' Club of Chicago to hold a meeting »

The Executives Club of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$276.40

0.92 (0.33%)

12:20
06/20/18
06/20
12:20
06/20/18
12:20
Options
Aggressive call spreads in SPYders »

Aggressive call spreads…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$202.58

5.12 (2.59%)

12:17
06/20/18
06/20
12:17
06/20/18
12:17
Hot Stocks
Facebook tests 'subscription groups' for administrators »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
06/20/18
06/20
12:17
06/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
06/20/18
06/20
12:16
06/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIG

Signet Jewelers

$60.04

2.91 (5.09%)

12:15
06/20/18
06/20
12:15
06/20/18
12:15
Options
Signet Jewelers put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.27

0.79 (0.29%)

12:14
06/20/18
06/20
12:14
06/20/18
12:14
Technical Analysis
Technical Take: SPDR S&P 500 ETF round-trips to session highs at midday »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.27

0.79 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$44.08

4.04 (10.09%)

, CLVS

Clovis

$47.48

1.74 (3.80%)

12:11
06/20/18
06/20
12:11
06/20/18
12:11
Recommendations
Tesaro, Clovis analyst commentary  »

SunTrust analysis yields…

TSRO

Tesaro

$44.08

4.04 (10.09%)

CLVS

Clovis

$47.48

1.74 (3.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

$17.52

0.42 (2.46%)

12:09
06/20/18
06/20
12:09
06/20/18
12:09
Hot Stocks
Altice says U.S .mobile service available in 2019,names Jean-Charles Nicolas SVP »

Altice USA announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$47.86

3.15 (7.05%)

, DIS

Disney

$106.00

-0.2 (-0.19%)

12:01
06/20/18
06/20
12:01
06/20/18
12:01
General news
On The Fly: Top stock stories at midday »

Stocks opened higher as…

FOXA

21st Century Fox

$47.86

3.15 (7.05%)

DIS

Disney

$106.00

-0.2 (-0.19%)

CMCSA

Comcast

$32.77

-0.04 (-0.12%)

GE

General Electric

$12.86

-0.105 (-0.81%)

WBA

Walgreens Boots Alliance

$67.72

3.11 (4.81%)

SBUX

Starbucks

$52.40

-5.03 (-8.76%)

ORCL

Oracle

$42.86

-3.43 (-7.41%)

FDX

FedEx

$253.85

-4.495 (-1.74%)

AMZN

Amazon.com

$1,755.30

19.56 (1.13%)

JPM

JPMorgan

$108.08

0.5 (0.46%)

BRK.A

Berkshire Hathaway

$285,450.00

-810 (-0.28%)

I

Intelsat

$19.52

3.46 (21.54%)

SYNA

Synaptics

$54.39

5.58 (11.43%)

DLGNF

Dialog Semiconductor

$0.00

(0.00%)

FOX

21st Century Fox

$47.24

2.96 (6.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 22

    Jun

  • 28

    Jun

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

  • 13

    Jul

  • 20

    Sep

  • 21

    Sep

  • 12

    Oct

T

AT&T

$32.02

-0.37 (-1.14%)

12:01
06/20/18
06/20
12:01
06/20/18
12:01
Periodicals
AT&T plans to acquire all of Otter Media, Recode reports »

AT&T intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHI

Sinopec Shanghai

$63.23

-4.37 (-6.46%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Sinopec Shanghai falls -6.4% »

Sinopec Shanghai is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$42.91

-3.38 (-7.30%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Oracle falls -7.3% »

Oracle is down -7.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEW

Puxin Limited

$26.90

-2.8 (-9.43%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Puxin Limited falls -10.9% »

Puxin Limited is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATU

Actuant

$28.40

2.45 (9.44%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Actuant rises 9.7% »

Actuant is up 9.7%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 27

    Jun

WGO

Winnebago

$45.75

5.35 (13.24%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Winnebago rises 13.6% »

Winnebago is up 13.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HAL

Halliburton

$45.85

-0.25 (-0.54%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Options
Second day of interest in Halliburton Aug 50 calls »

Second day of interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

I

Intelsat

$19.50

3.44 (21.42%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Intelsat rises 21.4% »

Intelsat is up 21.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$54.40

0.625 (1.16%)

11:57
06/20/18
06/20
11:57
06/20/18
11:57
Conference/Events
National Press Club to host a luncheon meeting »

Luncheon Meeting with Ed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

11:55
06/20/18
06/20
11:55
06/20/18
11:55
General news
Treasury Action: the 7s-10s spread is modestly wider at 4.1 bps »

Treasury Action: the…

11:55
06/20/18
06/20
11:55
06/20/18
11:55
General news
Euro$ interest rate futures are slightly lower »

Euro$ interest rate…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.